The BC Cancer Agency, in the November 2012 Systemic Therapy Update, has added bendamustine (Treanda®) to the Benefit Drug List
Bendamustine added to the BC Drug Benefit List for Relapsed Indolent Non-Hodgkin Lymphoma and Mantle Cell Lymphoma
The BC Cancer Agency, in the November 2012 Systemic Therapy Update, has added bendamustine (Treanda®) to the Benefit Drug List for the treatment of Relapsed Indolent Non-Hodgkin Lymphoma and Mantle Cell Lymphoma.
November 2012 Systemic Therapy Update
Bendamustine (Treanda®) offers patients an important new treatment option by extending their lives without having their disease progressing (cancer-free period). Lymphoma Canada (LC) welcomes the addition of this much needed therapy in BC, and commends the BC Cancer Agency for moving rapidly to meet the needs of Lymphoma patients in that province.
LC will continue to urge the other provinces in Canada to see this important treatment option made available to patients.
